Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?

SIMPLE SUMMARY: Since the identification of a large variety of biomarkers in B cell malignancies as being driving factors for tumor progression and patient prognosis, their targeting may confer valuable options for the treatment of these diseases. Over the past 20 years, the permanent development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tannoury, Mariana, Garnier, Delphine, Susin, Santos A., Bauvois, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775488/
https://www.ncbi.nlm.nih.gov/pubmed/36551511
http://dx.doi.org/10.3390/cancers14246026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775488/
https://www.ncbi.nlm.nih.gov/pubmed/36551511
http://dx.doi.org/10.3390/cancers14246026

Ejemplares similares